AstraZeneca today announced positive top-line results from the Phase III PINNACLE program, which included two pivotal 24-week studies (PINNACLE 1 and PINNACLE 2) to investigate the potential of PT003 to improve lung function in patients with Chronic Obstructive Pulmonary Disease (COPD).
PT003 is a twice-daily fixed-dose combination of glycopyrronium, a long-acting muscarinic antagonist (LAMA) and formoterol fumarate, a long-acting beta-2 agonist (LABA). PT003 is the first LAMA/LABA combination to be delivered in a pressurized metered dose inhaler (pMDI) using the unique porous particle co-suspension technology developed by Pearl Therapeutics, which was acquired by AstraZeneca in 2013. The development program also included assessment of the individual components of PT003 –glycopyrronium pMDI (PT001) and formoterol fumarate (PT005) pMDI. The successful completion of the PINNACLE studies marks the first Phase III outcomes from a series of pipeline candidates under development by AstraZeneca using Pearl’s novel technology.
In both the PINNACLE 1 and PINNACLE 2 studies, the primary objective was to assess benefits on lung function as measured by trough forced expiratory volume in one second (FEV1). PT003 demonstrated statistically significant improvements in trough FEV1 versus PT001, PT005 and placebo. Both PT001 and PT005 also demonstrated statistically significant improvements in trough FEV1 compared to placebo.
In PINNACLE 1 and PINNACLE 2, the most common adverse events across all treatment arms, including placebo, were nasopharyngitis, upper respiratory tract infection, and dyspnea. The incidence of adverse events was generally similar across all treatment groups. The Phase III program also included a 28-week extension study, PINNACLE 3, the safety information from which is not yet available.
Briggs Morrison, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These positive top-line results demonstrate the potential of PT003 as a novel treatment for patients suffering with the debilitating and chronic symptoms of COPD. The ability to deliver a unique LAMA/LABA formulation in a single pressurized metered dose device is important for helping some 30% of patients around the world who use an aerosol inhaler. Today’s results are also encouraging for the development of our investigative triple-drug combination of LAMA/LABA and inhaled corticosteroids.”
AstraZeneca plans to file global regulatory applications for PT003 commencing in 2015. Data from the PINNACLE 1, 2, and 3 Phase III studies will be presented at a scientific meeting later in the year.
NOTES TO EDITORS
The PINNACLE Phase III Pivotal Program
The PT003 Phase III pivotal program consists of PINNACLE 1, PINNACLE 2, and an extension study, PINNACLE 3. Overall the Phase III pivotal program enrolled over 3,700 patients with COPD at over 275 study sites.
PINNACLE 1 and PINNACLE 2 were Phase III randomized, double-blind, multi-center, placebo-controlled studies. In both studies, the efficacy and safety of PT003 administered twice daily via pressurized metered dose inhaler (pMDI) was compared to its monotherapy components: glycopyrronium (PT001), a LAMA, and formoterol fumarate (PT005), a LABA, and placebo. PT001 and PT005 were also compared to placebo. In PINNACLE 1, open-label tiotropium was included as an active control. Both studies were conducted over 24 weeks in subjects with COPD.
The primary objective of both studies was improvement in lung function as assessed by trough forced expiratory volume in one second (FEV1).
PINNACLE 3 was a multi-center, randomized, double blind, parallel-group, chronic dosing, active-controlled, 28 week safety extension study of the two pivotal 24 week studies (PINNACLE 1&2). It was designed to evaluate the long-term safety, tolerability, and efficacy of PT003 administered twice daily via pMDI compared to PT001 and PT005 in patients with moderate to very severe COPD over a total observation period of 52 weeks. Open-label tiotropium served as the active control.
COPD is a progressive disease characterized by persistent blockage of airflow from the lungs, primarily linked to tobacco smoking. Additional causes of COPD include air pollution and occupational exposure to dust and chemicals. People with COPD are likely to experience an acute worsening of symptoms, including breathlessness, mucus production, and chronic cough, which have been linked to a decline in lung function and overall health. COPD is rapidly becoming one of the world’s most serious health issues and is recognized as the third leading cause of death in the US. More than 12 million adult Americans are diagnosed with COPD, while an additional 12 million likely have the disease and remain undiagnosed.
About Pearl Therapeutics
Pearl Therapeutics is a wholly owned subsidiary of AstraZeneca, following its acquisition in 2013. The company is focused on developing inhaled combination therapies for the treatment of highly prevalent respiratory diseases, including COPD and asthma. Pearl Therapeutics’ unique porous particle co-suspension technology allows for the production of unique fixed-dose combinations of different classes of drugs at different concentrations in a single pressurized metered dose inhaler (pMDI) device – the most widely used inhalation delivery format.
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
|Esra Erkal-Paler||+44 20 7604 8030 (UK/Global)|
|Vanessa Rhodes||+44 20 7604 8037 (UK/Global)|
|Ayesha Bharmal||+44 20 7604 8034 (UK/Global)|
|Jacob Lund||+46 8 553 260 20 (Sweden)|
|Michele Meixell||+1 302 885 6351 (US)|
|Thomas Kudsk Larsen||+44 20 7604 8199 mob: +44 7818 524185|
|Karl Hård||+44 20 7604 8123 mob: +44 7789 654364|
|Eugenia Litz||+44 20 7604 8233 mob: +44 7884 735627|
|Craig Marks||+44 20 7604 8591 mob: +44 7881 615764|
|Christer Gruvris||+44 20 7604 8126 mob: +44 7827 836825|